Ampullary Adenocarcinoma
Conditions
Keywords
pancreatobiliary-type, intestinal-type, mixed/hybrid-type, adjuvant chemotherapy, CAPOX, FOLFIRINOX
Brief summary
Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype. Adjuvant therapy benefits only PB and mixed subtype patients, while prospective studies are required for validation. A study proposes tailored adjuvant treatments (CAPOX for intestinal subtype, FOLFIRINOX for PB and mixed subtypes) based on histopathology to enhance survival, also exploring molecular sub-studies for deeper insights.
Detailed description
Background: Ampullary adenocarcinoma(AAC) is rare. 5-year survival rates of 30% to 70% are seen after resection. This broad range of survival could be explained by the morphological heterogeneity in the three subtypes of AAC (pancreatobiliary, intestinal and mixed subtype), which complicates the prediction of individual prognosis and clinical decision making with regard to adjuvant therapy. To date there are no prospective studies to elucidate whether adjuvant chemotherapy improves survival in these patients. Methods/design: The ADAPTA study is a phase II prospective single arm multicenter cohort study including 200 patients with resected AAC (100 patients with intestinal subtype, and 100 with pancreatobiliary- and mixed subtype). All patients will be treated with CAPOX/ FOLFIRINOX respectively. Outcomes will be compared after propensity score matching to data of all patients in consecutive participating centers not treated according to the proposed regime.
Interventions
DRUGFolfirinox
Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study. The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice.
DRUGCapox
or 8 CAPOX cycles (Arm 1) every 3 weeks.
Sponsors
Associazione Italiana per la Ricerca sul Cancro
Fondazione Poliambulanza Istituto Ospedaliero
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult patients with histologically or cytologically confirmed AAC with subtyping of pancreatobiliary/mixed subtype or intestinal subtype * After curative resection for ampullary cancer without metastatic disease. * WHO performance status 0 or 1 * Able and willing to receive adjuvant chemotherapy * R0/ R1 resection * Age ≥ 18 years * Written informed consent
Exclusion criteria
* Prior radiotherapy, chemotherapy, or resection for AAC. * Previous malignancy (excluding non-melanoma skin cancer), unless no evidence of disease and diagnosed more than 5 years before diagnosis of AAC. * Pregnancy. * R2 resection. * Adjuvant chemotherapy started more than 12 weeks after surgery (aim to start within 8 weeks) * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator. * Known hypersensitivity or contraindications against capecitabine, 5 FU, Irinotecan, or Oxaliplatin * Inadequate organ functions, characterized by: * Leucocytes (WBC) \< 3.0 X 109/l * Neutrophils \< 1.500 (count per microliter of blood) * Platelets \< 100 x 109 /l * Hemoglobin \< 8 mmol/l * Renal function: E-GFR \< 50 ml/min (serum creatinine \< 1.5 x UNL) * cholestasis with elevated levels of bilirubin and/or alkaline phosphatase \> 3x UNL (can be improved by biliary drainage if necessary) * elevated transaminases (ALAT/ASAT) ≥ 5 x UNL * hypoalbuminemia \< 2.5 g/dl * Inadequate coagulation status INR \> 2 or Quick \< 50%, aPTT \>50 sec in the absence of any drugs interfering with coagulation such as acenocoumarin, warfarin, phenprocoumon, NMH or UFH.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (3y) | 3 years | Disease-free survival (DFS) refers to the length of time after treatment for a disease in months, such as cancer, during which no signs or symptoms of the disease recur or progress. It is a crucial measure in assessing the effectiveness of a treatment regimen in preventing the return of the disease. In cancer contexts, DFS focuses on the period without disease recurrence or progression, highlighting the success of the treatment in controlling the illness. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (3y) | 3 years | Overall survival (OS) is a critical medical outcome that measures the length of time in months from the start of treatment or diagnosis until a patient's death due to any cause. It provides a comprehensive view of the effectiveness of a treatment or intervention in extending a patient's life expectancy. OS is a fundamental endpoint in clinical trials and medical research, reflecting the real-world impact of medical strategies on patients' survival outcomes. |
| Disease-free survival (5y) | 5 years | Disease-free survival (DFS) refers to the length of time in months after treatment for a disease, such as cancer, during which no signs or symptoms of the disease recur or progress. It is a crucial measure in assessing the effectiveness of a treatment regimen in preventing the return of the disease. In cancer contexts, DFS focuses on the period without disease recurrence or progression, highlighting the success of the treatment in controlling the illness. |
| Overall survival (5y) | 5 years | Overall survival (OS) is a critical medical outcome that measures the length of time in months from the start of treatment or diagnosis until a patient's death due to any cause. It provides a comprehensive view of the effectiveness of a treatment or intervention in extending a patient's life expectancy. OS is a fundamental endpoint in clinical trials and medical research, reflecting the real-world impact of medical strategies on patients' survival outcomes. |
| Quality of Life questionnaire (qualitative outcome) | 3 years | Quality of life (QoL) is an essential outcome measure in clinical trials that assesses the overall well-being and satisfaction of patients throughout the course of a medical intervention or treatment. It encompasses various physical, emotional, social, and functional aspects of a patient's life, beyond just medical outcomes. QoL assessments provide valuable insights into how a treatment affects patients' daily functioning, emotional state, pain levels, social interactions, and overall sense of health and happiness. The questionnaires utilized in the ADAPTA study are the EQ-5D and the QLQ-C30. |
Countries
Italy
Contacts
Primary ContactMoh'd Abu Hilal, MD, PhD
Backup ContactBas Uijterwijk
Outcome results
None listed